Li Yunman

                Publisher:基礎醫學Release time:2017-12-26Times of browsing:189

                LI, YUNMAN

                Professor of Pharmacology

                Deputy Director of Basic Medicine,

                School of Basic Medicine and Clinical Pharmacy

                Phone: 025-83271173(O),


                Address: Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China

                Research Summary

                1. Cardiovascular and cerebrovascular pharmacology: anti cerebral ischemia, anti myocardial ischemia drug effect and effective signal pathway or target.

                2. Innovative drug of anti-ischemic stroke and anti-hemorrhagic stroke.

                3. Relationship between inflammatory factors, oxidative stress, immune and cerebral ischemia, myocardial ischemia, hyperlipidemia, atherosclerosis and hypertension, and drug intervention.

                4. The role of astrocytes and microglia in ischemic brain damage and drug intervention.


                2005, Ph.D., Pharmacology, China Pharmaceutical University

                1982, B.S., Medicine, Shandong Medical University

                Academic Experience

                I have been working on pharmacological research of cardiovascular drugs, tumor multidrug resistance reversal agents and have been engaged in teaching work of physiology and pharmacology for undergraduates, masters and doctoral students in China Pharmaceutical University. I have many years of lectures on human anatomy and physiology, basic pharmaceutical medicine, cardiovascular pharmacology for postgraduates, advances in pharmacology for postgraduates, pharmacological progress and molecular pharmacology for Ph.D. students. I have instructed 26 doctoral students and more than 80 master students. I enjoyed the special allowance of China Pharmaceutical University for 5 consecutive years from 2001 to 2005. In 2011, I was appraised as the instructor of the outstanding master’s degree thesis of Jiangsu province. I have hosted more than 20 of national and provincial research projects, published more than 100 of scientific research and teaching papers in core journals at home and abroad, of which more than 40 papers have been collected by SCI. I have been serving as executive director of the Jiangsu Institute of physiology, pharmacology and toxicology ninth Nanjing Pharmaceutical Association vice, director of Pharmacology Society of Jiangsu Province, member of the eleventh Committee of cardiovascular pharmacology of the Chinese Pharmacology Society, National health food review expert, National science and technology award evaluation experts, National 863 plan fund evaluation experts, National Nature Science Foundation evaluation experts, National development and Reform Commission drug price evaluation experts, Jiangsu Province health care food review experts. Besides, I acts as a reviewer of Central South Pharmacy, Chinese Journal of Clinical Pharmacology and Therapeutics, Journal of Experimental &Clinical Cancer Research, Journal of Pharmacy and Pharmacology, Acta Pharmacologica Sinica, Chinese Pharmacological Bulletin, Chinese Journal of New Drugs and Journal of China Pharmaceutical University.

                Award and Honors

                1. Advanced Worker of Jiangsu Pharmacology Society. 2015

                2. Excellent quality course of Jiangsu province. 2014.

                3. Excellent scientific book of Eastern Technology Press. 2014.

                4. Excellent Graduate Thesis of Master Degree. 2011. (Tutor)

                5. Excellent Editor for Journal of China Pharmaceutical University. 2009

                6. Most Cited Chinese Papers. 2008. Protective effects of scutellarin and borneolum injection on experimental cerebral ischemia in animals. Corresponding author

                7. Second kind of excellent quality course of China Pharmaceutical University. 2006. Ranking 3rd.

                8. Third prize of multi-media courseware of “Tiankong Jiaoshi Bei” of Jiangsu. 2006. Ranking 2nd.

                9. Second prize of excellent multi-media courseware of China Pharmaceutical University. 2006. Ranking 1st.

                10. First prize of excellent multi-media courseware of China Pharmaceutical University. 2005. Ranking 3rd.

                11. Science and Technology Production Identification Certificate of Jiangsu Province. 2004.10. Ranking 3rd.

                12. Science and Technology Production Finisher Certificate of Ministry of Education. Take charge of pharmacology

                13. Certificate of honor in science and technology of China Pharmaceutical University from 2001 to 2004.

                14. Excellent Editor for Chinese Pharmacological Bulletin

                15. Second Excellent Course of China Pharmaceutical University. Ranking 2nd.


                Papers and articles:

                1. Hu Y, Kodithuwakku N D, Zhou L, Li Y M(Corresponding Author), et al. Levo-Corydalmine Alleviates Neuropathic Cancer Pain Induced by Tumor Compression via the CCL2/CCR2 Pathway.[J]. Molecules, 2017, 22(6):937. (SCI, IF: 2.86)

                2. Mei Su, Chengyuan Li, Lin Zhou, Li Y M(Corresponding Author), et al. Anti-ulcerogenic effect of KFP-H008 against ethanol-induced gastric ulcer via p38 MAPK/NF-κB pathway[J]. Rsc Advances, 2017, 7(78):49423-49435. (SCI, IF: 3.11)

                3. Yan Y Y, Li C Y, Zhou L, Li Y M(Corresponding Author), et al. Research progress of mechanisms and drug therapy for neuropathic pain[J]. Life Sciences, 2017. (SCI, IF: 2.936)

                4. Su Y, Hu Y, Wang Y, Li Y M(Corresponding Author), et al. A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti-angiogenesis lung cancer therapy.[J]. Biomaterials, 2017, 139:75. (SCI, IF: 8.402)

                5. Huang L, Shang E, Fan W, Li Y M (Corresponding Author), et al. S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats[J]. European Journal of Pharmaceutical Sciences Official Journal of the European Federation for Pharmaceutical Sciences, 2017, 109. (SCI, IF: 3.756)

                6. Li C Y, Su M, Yan Y Y, Ao L Y, Fang W R, Li Y M (Corresponding Author). KFP-H008 Blocks Gastric Acid Secretion through inhibiting H+-K+-ATPase.[J]. European Journal of Pharmacology, 2017, 810:112. (SCI, IF: 2.896)

                7. Fei Y X, Wang S Q, Yang L J, Fang W R, Li Y M (Corresponding Author). Salvia miltiorrhiza Bunge (Danshen) extract attenuates permanent cerebral ischemia through inhibiting platelet activation in rats.[J]. Journal of Ethnopharmacology, 2017, 207. (SCI, IF: 2.981)

                8. Dan H, Jie W, Rui Z, Li Y M (Corresponding Author), et al. Hydroxysafflor yellow A alleviates myocardial ischemia/reperfusion in hyperlipidemic animals through the suppression of TLR4 signaling[J]. Sci Rep, 2016, 6:35319. (SCI, IF: 4.26)

                9. Yang L, Chen X, Wang S, Li Y M (Corresponding Author), et al. N2 extenuates experimental ischemic stroke through platelet aggregation inhibition[J]. Thrombosis Research, 2015, 136(6):1310.SCI, IF: 2.65

                10. Han D, Fang W, Zhang R, Wei J, Kodithuwakku ND, Sha L, Ma W1, Liu L, Li F, Li YCorresponding Author. Clematichinenoside protects blood brain barrier against ischemic stroke superimposed on systemic inflammatory challenges through up-regulating A20. Brain Behav Immun. 2016; 51: 56-69. (SCI, IF: 5.889)

                11. Liu C, Du Q, Zhang X, Tang Z, Ji H, Li YCorresponding Author. Clematichinenoside Serves as a Neuroprotective Agent Against Ischemic Stroke: The Synergistic Action of ERK1/2 and cPKC Pathways. Front Cell Neurosci. 2016; 9:517.( SCI, IF4.3)

                12. Simin Yan a,b, Xu Zhang b, Haili Zheng b, Danhong Hu b, Yongtian Zhang b, Qinghua Guan b,Lifang Liu c, Qilong Ding b,n, Yunman LiCorresponding Authora,n,Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-α-treated endothelial cells via NADPH oxidase-dependent IκB kinase/NF-κB pathway ,Free Radical Biology and Medicine 78 (2015) 190–201. (SCI, IF5.71)

                13. Huang J, Kodithuwakku ND, He W, Zhou Y, Fan W, Fang W, He G, Wu Q, Chu S, Li YCorresponding Author. The neuroprotective effect of a novel agent N2 on rat cerebral ischemia associated with the activation of PI3K/Akt signaling pathway. Neuropharmacology.  95 (2015): 12-21. (SCI, IF5.106)

                14. Fang W, Sha L, Kodithuwakku ND, Wei J, Zhang R, Han D, Mao L, Li YCorresponding Author. Attenuated Blood-Brain Barrier Dysfunction by XQ-1H Following Ischemic Stroke in Hyperlipidemic Rats. Mol Neurobiol. 2015; 52(1): 162-75. (SCI, IF: 5.137)

                15. Yanyan Zhang a, Yidong Feng a, Kodithuwakku Nandani Darshika a, Bo Zhang a, Yahui Hu a, Weirong Fang a,Yunman Lia, Corresponding Author, Wenlong Huang b,The effect of multidrug resistance modulator HZ08 onpharmacodynamics and pharmacokinetics of adriamycin in xenograft-nude mice. European Journal of Pharmaceutical Sciences 66 (2015) 109–117.SCI, IF3.005

                16. Hu Z, Zhou Z, Hu Y, Wu J, Li YCorresponding Author, Huang W. HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo. PLoS One. 2015; 10(2): e0116886. ( SCI, IF3.234)

                17. Kodithuwakku ND, Feng YD, Zhang YY, Pan M, Fang WR, Li YMCorresponding Author. The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice. J Ethnopharmacol. 163 (2015): 278-89 (SCI, IF3.055)

                18. Weirong Fang, Rui Zhang, Lan Sha, Peng Lv, Erxin Shang, Dan Han, Jie Wei, Xiaohan Geng, Qichuan Yang, Yunman LiCorresponding Author. Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain. J Neurochem.  (2014) 128, 662–671.SCI, IF3.973

                19. Yan-Yan Zhanga, Ya-Hui Hua, Yi-Dong Fenga, Kodithuwakku Nandani Darshikaa, Wei-Rong Fanga, Yun-Man Lia*Corresponding Author, Wen-Long Huangb.The inhibitory and combinative mechanism of HZ08 with P-glycoprotein expressed on the membrane of Caco-2 cell line .Toxicology and Applied Pharmacology.  2742014232-239.SCI, IF3.973

                20. Xiong, Y., Ma, Y., Han, W., Kodithuwakku, N.D., Liu, L.F., Li, F.W., Fang, W.R., Li, Y.M iCorresponding Author. Clematichinenoside AR induces immunosuppression involving Treg cells in Peyers patches of rats with adjuvant induced arthritis. Journal of ethnopharmacology 2014. 155(2): 1306-14. SCI, IF2.755

                21. Yi Zhou, Jinru Huang, Wei He, Wenxiang Fan, Weirong Fang, Guang-wei He, Qiang Wu, Shaoxing Chu, Yunman LiCorresponding Author),N2 ameliorates neural injury in experimental ischemic stroke via regulation of thromboxane A2 production. Pharmacology, Biochemistry and Behavior 124 (2014) 458–465. SCI, IF2.82

                22. Weirong Fanga, 1, Jie Weia, 1, Dan Hana, Xi Chena, Guangwei Heb, Qiang Wub, Shaoxing Chub, Yunman LiCorresponding Author),MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition. Thrombosis Research,133(2014)610-615.SCI, IF2.427)。

                23. Kodithuwakku, N.D., M. Pan, Y.L. Zhu, Y.Y. Zhang, Y.D. Feng, W.R. Fang, and Y.M. LiCorresponding Author, Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis. J Ethnopharmacol, 2013. 150(3): p. 1071-9.SCI, IF2.936

                24. Weirong Fang, Peng Lv, Xiaohan Geng, Erxin Shang, Qichuan Yang, Lan Sha, Yunman LiCorresponding Author.. Penetration of verapamil across blood brain barrier following cerebral ischemia depending on both paracellular pathway and P-glycoprotein transportation. Neurochem Int. 62 (2013) 23–30.SCI, IF2.857)。

                25. Yidong Feng a, Yahui Hu a, Juan Cen a, Kodithuwakku Nandani Darshika a, Weirong Fang a,Yunman Lia*Corresponding Author, Wenlong Huang b. HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. European Journal of Pharmacology 712 (2013) 53–59.SCI, IF2.592)。

                26. Yan  Qia,  Jing-Yan Geb, Yi-Nan Wangc ,Hai-Yan Liub, Yun-Man Lia*Corresponding Author, Zhong-Hui Liub,?, Xue-Ling Cuib,? Co-expression of activin receptor-interacting protein 1 and 2 in mouse nerve cells. Neuroscience Letters 542 (2013) 53– 58. SCI, IF2.026

                27. Yi-dong Feng, Wei-rong Fang,Yun-man LiCorresponding Author. HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. [J]. Acta Pharmacol Sin,Vol.34, Supplement July 2013. SCI, IF2.51

                28. Weirong Fang, Peng Lv, Xiaohan Geng, Erxin Shang, Qichuan Yang, Lan Sha, Yunman LiCorresponding Author.. Penetration of verapamil across blood brain barrier following cerebral ischemia depending on both paracellular pathway and P-glycoprotein transportation. Neurochem Int. 62 (2013) 23–30.SCI, IF2.857)。

                29. Wei J, Fang W, Sha L, Han D, Zhang R, Hao X, Li YCorresponding Author. XQ-1H Suppresses Neutrophils Infiltration and Oxidative Stress Induced by Cerebral Ischemia Injury Both In Vivo and In Vitro. Neurochem Res. 2013; 38: 2542-2549 (SCI, IF2.551)

                30. Yi-dong Feng, Wei-rong Fang,Yun-man LiCorresponding Author. HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. [J]. Acta Pharmacol Sin,Vol.34, Supplement July 2013. SCI, IF2.51

                31. Qian, Yisong, Guan, Teng, Huang, Menghao, Cao, Liangxun, *Li, YunmanCorresponding Author, Cheng, Hao, Jin, Hangxia, Yu, Deyue,Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-kappa B activation in a cerebral ischemia mouse model[J],Neurochemistry International, 60(8), pp 759-767, 2012/6. SCI, IF2.857

                32. Jing Xiong a,b,1, Li Baib,1, Wei Fang c, Jianyang Fu b, Weirong Fang b, Juan Cen b, Yi Kong d,*, Yunman Lib,* Corresponding Author. New peptide pENW (pGlu-Asn-Trp) inhibits platelet activation by attenuating Akt phosphorylation. European Journal of Pharmaceutical Sciences.45 (2012) 552–558. SCI, IF3.2

                33. Menghao Huang 1, Yisong Qian 1, Teng Guan 1, Longfei Huang, Xuzhen Tang, Yunman Li Corresponding Author*.Different neuroprotective responses of Ginkgolide B and bilobalide, the two Ginkgo. European Journal of Pharmacology 677 (2012) 71–76. SCI, IF2.516

                34. Qichuan Yang, Weirong Fang , Peng Lv, Xiaohan Geng ,Yunman Li* Corresponding AuthorLan Sha. Therapeutic Neuroprotective Effects of XQ-1H in a Rat Model of Permanent Focal Cerebral Ischemia. Pharmacology  2012;89:1–6. SCI, IF1.82

                35. Y-L Zhu1,J Cen2, Y-Y Zhang 1 , Y-D Feng1, Y Yang1 , Y-M Li1*Corresponding Author, W-L Huang3. The Multidrug Resistant Modulator HZ08 Reverses Multidrug Resistance via P-glycoprotein Inhibition and Apoptosis Sensitization in Human Epidermoid Carcinoma Cell Line KBv200. Bibliography. February 16, 2012. SCI, IF0.82

                36. Jing Xiong1,2, Virginia M. Miller2,3*, Larry W. Hunter2, Yunman Li*(Corresponding Author), Muthuvel Jayachandran3. Leukocyte- and Platelet-Derived Microvesicle Interactions following In Vitro and In Vivo Activation of Toll-Like Receptor 4 by Lipopolysaccharide. PLoS ONE.September 2011 | Volume 6 | Issue 9.SCI, IF4.41

                37. Lv P, Fang W, Geng X, Yang Q, Li YCorresponding Author, Sha L. Therapeutic neuroprotective effects of ginkgolide B on cortex and basal ganglia in a rat model of transient focal ischemia. Eur J Pharm Sci. 2011; 44(3): 235-40 。IF 3.291SCI, IF3.291

                38. Zhen X, Cen J, Li  YMCorresponding Author, Yan F, Guan T, Tang XZ. Cytotoxic effect and apoptotic mechanism of tanshinone A, a novel tanshinone derivative, on human erythroleukemic K562 cells. Eur J Pharmacol. 2011; 667(1-3): 129-35.SCI, IF2.787

                39. Fang W, Geng X, Deng Y, Li Y(Corresponding Author), Shang E, Cen J, Lv P: Platelet activating factor induces blood brain barrier permeability alteration in vitro. J Neuroimmunol, 2011, 230(1-2):42-47. IF 2.98SCI, IF2.98

                40. Sun J, Li YCorresponding Author, Fang W, Mao L. Therapeutic time window for treatment of focal cerebral ischemia reperfusion injury with XQ-1h in rats. Eur J Pharmacol. 2011; 666(1-3): 105-10. SCI, IF2.787

                41. Longfei Huang a,1, Teng Guan a,1, Yisong Qian a,1, Yunman LiaCorresponding Author, Hongbin Sun b.Anti-in?ammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B. Eur J Pharmacol. 672 (2011) 169–174. SCI, IF2.787

                42. Perera PK, Peng C, Xue L, Li YCorresponding Author, Han C. Ex vivo and in vivo effect of Chinese herbal pill Yi Shen Juan Bi (YJB) on experimental arthritis. J Ethnopharmacol. 2011; 134(1): 171-5.SCI, IF2.936

                43. Juan Cen, Yan Qi, Yunman Li(Corresponding Author), Weirong Fang, Yan Deng, Lu-yong Zhang, Wenlong Huang.HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM. European Journal of Pharmacology. 2010; 6471-3: 21-30. SCI, IF2.787

                44. Yan Deng, Weirong Fang, Yunman Li(Corresponding Author), Juan Cen, Fang Fang, Peng Lv, Shubo Gong, Lishun Mao. Blood-brain barrier breakdown by PAF and protection by XQ-1H due to antagonism of PAF effects. European Journal of Pharmacology, 2009, 616 (1-3): 43-47.SCI, IF2.787


                      1. Yunman Li (editor), Weirong Fang. Caodiovascular Pharmacology. Science and Technology Press of Jiangsu. 2014.3. 1st edition.

                      2. Yijia Lou, Yunman Li (associate editor). Drug Toxicology. People’s Medicinal Publishing House. Beijing. 2011.7.

                      3. Qilong Ding, Yunman Li ( editor). Experiment and Guide for Physiology. Beijing: China Medicine Tecnology Press. 2004.3

                      4. Chart 35: Molecular base of Nervous System Drugs. Current Pharmacology. Peking Union Medical College Press. 2008.5, 2nd edition.

                      5. Associate editor. Human Anatomy and Physiology. China Medical Science and Technology press. 2009.8. 1st edition.

                The subject of scientific research:

                Provincial and national topics:

                1. National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-year Plan Period (No. 2016ZX09101031)

                2. National Natural Science Foundation (No. 81173088), 2012.01 - 2015.12, as the project host.

                3. The Ministry of Education Research Fund for the doctoral program (Ph.D. category), No. 20120096110004, 2013.01 - 2015.12, as the project host.

                4. Jiangsu high tech program fund, No. BY2014129, as the project host.

                5. Jiangsu new drug creation fund, No: 0512036, as the host of the project.

                6. Jiangsu high technology plan fund, No: BG2007613, as the project host.

                7. Jiangsu provincial science and Technology Commission social development fund, No: BS96016, as the project host.

                8. National Natural Science Foundation, No. 30772770.

                9. Jiangsu new drug creation fund, No: 0709040.

                10. National new drug development special fund (candidate drug) project number: 2009ZX09103-371, I am the Deputy group leader of the project.

                11. The national science and technology major project "major new drug development" (candidate drug) (No.2009ZX09103-093).

                12. The national science and technology major project "major new drug development" (pre clinical research project), project number: 2009ZX09102-036.

                13. National Science and technology major project "major new drug development" (pre clinical research project), project number: 2002AA 233071.

                14. The national major project 12th Five-Year, "major new drug development" (pre-clinical research project), No: 2012ZX09102101.

                15. National Science and technology 12th Five-Year major project "major new drug development" (pre clinical research project), No: 2013ZX09301303005.

                16. National 863 Program Fund, project number: 2002AA 233071, 2002.01- 2005.01.

                17. Doctoral Fund of State Ministry of education, project number: 20040316005, 2004.03. - 2006.12.

                18. Doctoral Fund of higher education project number: Y071013. 2007.10. - 2009.10.

                19. The Ministry of education "2005 new century outstanding talent support program" funded project, project number: NCET-05-0495, 2005.04. - 2006.12.

                20. National 95 key projects, subject number: 696-902-03-07.

                21. The new drug creation fund of Jiangsu province.2002.01 - 2005.12

                22. National new drug research fund, No: 96-901-05-65.

                23. National innovation project, 2007.01 – 2008.01.


                A total of 12 patents were applied, including 3 for the first inventors, 3 for second inventors, 5 for third inventors, 1 for fourth inventors, and 1 for sixth inventors.

                10 invention patent certificate: 3 for the first inventor, 1 for the second inventors, 5 for the third inventors, 1 for the fourth inventors.

                New drug certificates:

                1. The total saponins of Dipsacus extracts (the original two kinds of traditional Chinese Medicine), Zhunzi Z20070053, Zhejiang Dier Pharmaceutical Co Ltd, China Medicine University.

                2. Xuduanzhuanggu capsule (the original two kinds of traditional Chinese Medicine), Zhunzi Z20070054, Zhejiang Dier Pharmaceutical Co Ltd, China Medicine University.

                Drug clinical trial approval certificates:

                1. September 10, 2015, Qing Xin cold particles (admissibility: CXZL1200009) drug clinical trial document, Document No. 2015L01797.

                2. 2008, Roselle compound oral liquid, approval of clinical trial of drugs: 2008L00381.

                3. 2011, Ginkgolide methanesulfonate B (medicine 1.1), clinical approval document No. 1, 2011L1008.

                4. The dogwood terpene tablet clinical trial document, Document No. 2011L02622, acceptance number: CXZL1000019.